[Creatine kinase BB activity in the serum of patients with cerebrovascular diseases]

Der Nervenarzt
|August 1, 1985
PubMed

Insights

Serum creatine kinase BB isoenzyme (CK-BB) levels increase significantly with the severity of cerebrovascular disease lesions. Severe lesions showed peak CK-BB activity on day one post-symptoms, indicating its potential as a biomarker.

Area of Science:

  • Biochemistry
  • Neurology
  • Medical Diagnostics

Context:

  • Conflicting reports exist regarding creatine kinase BB isoenzyme (CK-BB) activity in cerebrovascular disease.
  • Accurate assessment of CK-BB levels is crucial for understanding its role in neurological conditions.

Purpose:

  • To investigate the correlation between serum CK-BB activity and the extent of brain lesions in patients with cerebrovascular disease.
  • To clarify the diagnostic utility of CK-BB in differentiating lesion severity.

Summary:

  • Serum CK-BB activity was measured in 33 patients with ischemic brain infarction, subarachnoid hemorrhage, or intracerebral hemorrhage using a bioluminescence method and immunoprecipitation.
  • A significant elevation in CK-BB activity was observed in patients with more extensive and severe brain lesions compared to controls.
  • Patients with severe lesions exhibited peak CK-BB activity on the first day following symptom onset.

Impact:

  • This study provides evidence that elevated serum CK-BB levels are associated with the severity of cerebrovascular lesions.
  • Findings suggest CK-BB may serve as a valuable biomarker for assessing the extent of brain damage in cerebrovascular events.
  • The temporal profile of CK-BB elevation, particularly its peak on day one in severe cases, offers insights for clinical monitoring.